Pattern of Retinopathy: Although the locus of toxic damage is parafoveal in many eyes, Asian patients often show an extramacular pattern of damage. Dose: We recommend a maximum daily HCQ use of 5.0 mg/kg real weight, which correlates better with risk than ideal weight. Trametinib and hydroxychloroquine Plaquenil ocular toxicity Half life of plaquenil May 02, 2007 Here is an eye test that is easy for all of us to do online, without going to the doctor right away. Scroll down after you go to this site until a graph shows up with a dot in the center. Look at the dot with one eye at a time, and if the lines change, then you might need to see the doctor. Eye care specialists provide a valuable service when screening for Plaquenil retinal toxicity and advising the treating physician or rheumatologist with regards to the patient’s risk, safe dosing and appropriate screening procedures. Eye damage due to Plaquenil is not common,” he says. “Rarely will anybody who has good vision and minimal symptoms develop loss of central vision or ability to read if annual screening is done and visual are symptoms reported as soon as they occur so the medication can be stopped if toxicity occurs. Risk of Toxicity: The risk of toxicity is dependent on daily dose and duration of use. There are no similar demographic data for CQ, but dose comparisons in older literature suggest using 2.3 mg/kg real weight. Plaquenil screening eye exam Plaquenil screening eye exam, hydroxychloroquine toxicity - A., How to Succeed in Plaquenil Screenings Retinal changes with the use of hydroxychloroquine When you visit an ophthalmologist for a Plaquenil eye exam, your doctor will perform different tests to detect the presence or extent of retinal damage due to this medication. A Plaquenil screening may include a visual field test, OCT imaging, multifocal ERG, and photos of your eye. Plaquenil Eye Exams - Rock Hill Eye Center. Protecting your eyesight when taking Plaquenil Lupus.. Starting Plaquenil BEFORE Eye Exam? - Scleroderma - Inspire. Baseline Examination All patients should have a baseline ophthalmologic examination within the first year of initiating HCQ or CQ therapy with thorough risk factor assessment and fundus examination of the macula to rule out underlying disease. Baseline visual field and SD OCT are recommended if abnormalities are present e.g. macular lesions, glaucoma, etc that could affect screening tests. Macular Society Eye screening for patients taking hydroxychloroquine. Hydroxychloroquine is a medication used to treat several conditions including rheumatoid arthritis, systemic lupus erythematosus, some skin conditions especially photosensitive ones and others that involve inflammation. Remember, any patient who is at a high risk for Plaquenil toxicity should be examined on an annual basis following the baseline exam. The goal of monitoring/screening is to identify early macular damage prior to irreversible vision loss or even before visible signs of bull’s eye maculopathy.